相似文献
1
Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia.
Leukemia. 2021 Aug;35(8):2403-2406. doi: 10.1038/s41375-021-01128-1. Epub 2021 Jan 22.
2
Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
Blood. 2011 Aug 25;118(8):2222-38. doi: 10.1182/blood-2011-03-342774. Epub 2011 Jun 29.
3
Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
Blood. 2020 Sep 17;136(12):1460-1465. doi: 10.1182/blood.2020005610.
4
Clinical and biological aspects of myeloid leukemia in Down syndrome.
Leukemia. 2021 Dec;35(12):3352-3360. doi: 10.1038/s41375-021-01414-y. Epub 2021 Sep 13.
5
[Abnormal hematopoiesis in Down syndrome].
Rinsho Ketsueki. 2014 Oct;55(10):1738-47.
6
Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.
Leukemia. 2021 Sep;35(9):2508-2516. doi: 10.1038/s41375-021-01157-w. Epub 2021 Feb 15.
7
Detection of a clone-specific GATA1 mutation to monitor treatment response and involvement of a monozygotic twin in myeloid leukemia of Down syndrome.
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26439. Epub 2017 Jan 11.
8
Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
Genes Chromosomes Cancer. 2020 Mar;59(3):160-167. doi: 10.1002/gcc.22816. Epub 2019 Oct 21.
9
Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Cancer Cell. 2019 Aug 12;36(2):123-138.e10. doi: 10.1016/j.ccell.2019.06.007. Epub 2019 Jul 11.
10
Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
Blood. 2010 Nov 25;116(22):4631-8. doi: 10.1182/blood-2010-05-282426. Epub 2010 Aug 20.
引用本文的文献
1
Genome-wide association study of somatic GATA1s mutations in newborns with Down syndrome.
Blood Adv. 2025 Aug 26;9(16):4235-4243. doi: 10.1182/bloodadvances.2025016282.
2
Down syndrome-associated leukaemias: current evidence and challenges.
Ther Adv Hematol. 2024 Jul 23;15:20406207241257901. doi: 10.1177/20406207241257901. eCollection 2024.
3
Minimal Infiltrative Disease Identification in Cryopreserved Ovarian Tissue of Girls with Cancer for Future Use: A Systematic Review.
Cancers (Basel). 2023 Aug 22;15(17):4199. doi: 10.3390/cancers15174199.
4
Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis.
Leukemia. 2023 Aug;37(8):1589-1599. doi: 10.1038/s41375-023-01955-4. Epub 2023 Jul 1.
5
Weighted gene co-expression network analysis identifies key hub genes and pathways in acute myeloid leukemia.
Front Genet. 2023 Feb 27;14:1009462. doi: 10.3389/fgene.2023.1009462. eCollection 2023.
6
Clinical practice - latest insights in optimizing the care of children with Down syndrome.
Eur J Pediatr. 2023 May;182(5):2027-2039. doi: 10.1007/s00431-023-04890-9. Epub 2023 Mar 10.
7
Leukemogenesis in infants and young children with trisomy 21.
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):1-8. doi: 10.1182/hematology.2022000395.
8
Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn.
Blood Adv. 2022 May 10;6(9):2893-2896. doi: 10.1182/bloodadvances.2021006865.
Zotero 插件